NCT00664274

Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia

COMT Genotype and Response to Cognitive Remediation in Schizophrenia

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 142 (estimated)
• Sponsor: Manhattan Psychiatric Center · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

This project will explore the relationship between catechol-O-methyltransferase (COMT) Val158/108Met genotype and response to a 12-week computerized neurocognitive rehabilitation (CRT) given to chronic schizophrenic patients.

Detailed description

Cognitive deficits play a crucial role in both the pathogenesis and prognosis of schizophrenia. The COMT gene is functionally expressed in neural systems considered important in a range of healthy brain functions and brain disorders, including schizophrenia. The COMT Met allele has been shown to be associated with a lower activity form of COMT, and with better performance on neurocognitive tests, while the COMT Val allele is associated with poorer executive cognition. This study will investigate the relationship of COMT polymorphism in patients with chronic schizophrenia with the response to CRT targeting visuospatial processing, attention, and cognitive flexibility using MATRICS Consensus Cognitive Battery (MCCB) developed by the NIH-MATRICS initiative.

Conditions

• Chronic Schizophrenia

Interventions

Type	Name	Description
BEHAVIORAL	Cognitive remediation therapy	36 sessions of Computerized Cognitive Skills Training, 3 per week for 12 weeks.
GENETIC	COMT Genotyping	One time saliva sample is taken to genotype catechol-O-methyltransferase Val158/108Met alleles.

Timeline

• Start date: 2007-04-01
• Primary completion: 2015-01-01
• Completion: 2016-10-01
• First posted: 2008-04-22
• Last updated: 2015-04-17

Locations

1 site across 1 country: United States